The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Flagged first, then by citations
2 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,007
Goldkorn, T., Filosto, S., & Chung, S. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5469 · Cited by 106
Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers
Hecht, S. S., Kassie, F., & Hatsukami, D. K. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2674 · Cited by 104
Li, H., Pan, Y., Li, Y., Li, C., Wang, R., Hu, H., Zhang, Y., Ye, T., Wang, L., Shen, L., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.018 · Cited by 104
Tan, Y. C., Krishnaswamy, S., Nandi, S., Kanteti, R., Vora, S., Onel, K., Hasina, R., Lo, F.-Y., El‐Hashani, E., Cervantes, G. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008972 · Cited by 104
The Impact of Genomic Changes on Treatment of Lung Cancer
Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 103
Self-citationMutations of theEPHA2receptor tyrosine kinase gene cause autosomal dominant congenital cataract
Zhang, T., Hua, R., Xiao, W., Burdon, K. P., Bhattacharya, S. S., Craig, J. E., Shang, D., Zhao, X., Mackey, D. A., Moore, A. T., et al. (2009) · Human Mutation · doi:10.1002/humu.20995 · Cited by 103
Self-citationSox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer
Mukhopadhyay, A., Berrett, K. C., Kc, U., Clair, P. M., Pop, S., Carr, S. R., Witt, B. L., & Oliver, T. G. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.036 · Cited by 102
Targeted Therapies for Lung Cancer
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 106
FGFR Signaling as a Target for Lung Cancer Therapy
Desai, A., & Adjei, A. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.08.003 · Cited by 107
Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM -Defective Tumors
Riabinska, A., Daheim, M., Herter-Sprie, G. S., Winkler, J., Fritz, C., Hallek, M. J., Thomas, R. K., Kreuzer, K., Frenzel, L. P., Monfared, P., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005814 · Cited by 103
Self-citationTaming the dragon: genomic biomarkers to individualize the treatment of cancer
Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 101
Marshall, M. E., Hinz, T. K., Kono, S. A., Singleton, K. R., Bichon, B., Ware, K. E., Marek, L. A., Frederick, B. A., Raben, D., & Heasley, L. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0050 · Cited by 102
Wang, B., Ceniccola, K., Hwang, S., Andrawis, R., Horvath, A., Freedman, J. A., Olender, J., Knapp, S., Ching, T. H., Garmire, L. X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15921 · Cited by 105
Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression
Warren, C. J., Westrich, J. A., Doorslaer, K. V., & Pyeon, D. (2017) · Viruses · doi:10.3390/v9080233 · Cited by 105
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 109
Self-citationBRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chen, D., Zhang, L.-Q., Huang, J.-F., Liu, K., Chuai, Z.-R., Yang, Z., Wang, Y., Shi, D., Liu, Q., Huang, Q. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101354 · Cited by 102
Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
Gao, W., Wang, M. L., Wang, L., Lu, H., Wu, S., Dai, B., Ou, Z., Zhang, L., Heymach, J. V., Gold, K. A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju204 · Cited by 101
Self-citationLiu, W., Lindberg, J., Sui, G., Luo, J., Egevad, L., Li, T., Xie, C., Wan, M., Kim, S.-T., Wang, Z., et al. (2011) · Oncogene · doi:10.1038/onc.2011.554 · Cited by 100
Tran, P. T., Shroff, E. H., Burns, T. F., Thiyagarajan, S., Das, S., Zabuawala, T., Chen, J., Cho, Y., Luong, R. H., Tamayo, P., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002650 · Cited by 108
Personalized medicine for lung cancer: new challenges for pathology
Kerr, K. M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03854.x · Cited by 104
Girard, N., Deshpande, C. G., Azzoli, C. G., Rusch, V. W., Travis, W. D., Ladanyi, M., & Pao, W. J. (2009) · CHEST Journal · doi:10.1378/chest.09-0325 · Cited by 99
Self-citationRole of cell cycle regulators in lung carcinogenesis
Eymin, B., & Gazzéri, S. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10977 · Cited by 98
González-Pérez, A., Deu-Pons, J., & López-Bigas, N. (2012) · Genome Medicine · doi:10.1186/gm390 · Cited by 98
Sunaga, N., Imai, H., Shimizu, K., Shames, D. S., Kakegawa, S., Girard, L., Sato, M., Kaira, K., Ishizuka, T., Gazdar, A. F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26164 · Cited by 103
Genetic modeling of gliomas in mice: New tools to tackle old problems
Hambardzumyan, D., Parada, L. F., Holland, E. C., & Charest, A. (2011) · Glia · doi:10.1002/glia.21142 · Cited by 107
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer
Velic, D., Couturier, A. M., Ferreira, M., Rodrigue, A., Poirier, G. G., Fleury, F., & Masson, J. (2015) · Biomolecules · doi:10.3390/biom5043204 · Cited by 106
TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Kummar, S., & Lassen, U. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0590-1 · Cited by 98
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression
Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, J. A., Neely, G. G., Zwick, R. H., Sigl, V., Forni, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.767 · Cited by 99
Lee, S. Y., Kim, M. J., Jin, G., Yoo, S. S., Park, J. Y., Choi, J. E., Jeon, H. S., Cho, S., Lee, E. B., Cha, S. I., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f0beca · Cited by 97
Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer
Okamura, K., Harada, T., Wang, S., Ijichi, K., Furuyama, K., Koga, T., Okamoto, T., Takayama, K., Yano, T., & Nakanishi, Y. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.07.011 · Cited by 99
Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
Wong, K. M., Hudson, T. J., & McPherson, J. D. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141532 · Cited by 96
Roper, N., Gao, S., Maity, T. K., Banday, A. R., Zhang, X., Venugopalan, A. K., Cultraro, C. M., Patidar, R., Sindiri, S., Brown, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2019.02.028 · Cited by 97
Guan, H., Zhu, T., Wu, S., Liu, S., Liu, B., Wu, J., Cai, J., Zhu, X., Zhang, X., Zeng, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900997116 · Cited by 97
Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97
Concepts and consequences of Eph receptor clustering
Janes, P. W., Nievergall, E., & Lackmann, M. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.001 · Cited by 96
Luo, L., McGarvey, P. B., Madhavan, S., Kumar, R., Gusev, Y., & Upadhyay, G. (2016) · Oncotarget · doi:10.18632/oncotarget.7163 · Cited by 99
Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96
Drug radiotherapy combinations: Review of previous failures and reasons for future optimism
Higgins, G. S., O'Cathail, S. M., Muschel, R. J., & McKenna, W. G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.012 · Cited by 99
Li, C., Sun, Y., Fang, R., Han, X., Luo, X., Wang, R., Pan, Y., Hu, H., Zhang, Y., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318234f0a2 · Cited by 96
Self-citationUncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis
Young, N. P., Crowley, D. G., & Jacks, T. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4563 · Cited by 91
Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
Gurpinar, E., & Vousden, K. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.04.001 · Cited by 98
Eph-dependent cell-cell adhesion and segregation in development and cancer
Nievergall, E., Lackmann, M., & Janes, P. W. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0900-6 · Cited by 96
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 95
Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas
Gao, B., Sun, Y., Zhang, J., Ren, Y., Fang, R., Han, X., Shen, L., Liu, X., Pao, W. J., Chen, H., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e05016 · Cited by 98
Self-citationAgarwal, S., Bell, C. M., Rothbart, S. B., & Moran, R. G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665133 · Cited by 97
The emerging role of microRNAs in resistance to lung cancer treatments
MacDonagh, L., Gray, S. G., Finn, S. P., Cuffe, S. D., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.009 · Cited by 92
Early Detection of Lung Cancer in Serum by a Panel of MicroRNA Biomarkers
Wang, P., Yang, D., Zhang, H., Wei, X., Ma, T., Cheng, Z., Hong, Q., Hu, J., Zhuo, H., Song, Y., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.006 · Cited by 93
The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics
Abdel-Wahab, O. I., & Dey, A. (2012) · Leukemia · doi:10.1038/leu.2012.288 · Cited by 97
Wu, X., Ye, Y., Rosell, R., Amos, C. I., Stewart, D. J., Hildebrandt, M. A. T., Roth, J. A., Minna, J. D., Gu, J. H., Lin, J. M., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr075 · Cited by 94
Self-citationA network-based biomarker approach for molecular investigation and diagnosis of lung cancer
Wang, Y., & Chen, B. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-2 · Cited by 93
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung
Hwang, D. H., Sholl, L. M., Rojas‐Rudilla, V., Hall, D. L., Shivdasani, P., Garcia, E. P., MacConaill, L. E., Vivero, M., Hornick, J. L., Kuo, F. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.010 · Cited by 93
Vescovo, V. D., & Denti, M. A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-23730-5_9 · Cited by 92
Tan, M., Zhao, Y., Kim, S.-J., Liu, M., Jia, L., Saunders, T. L., Zhu, Y., & Sun, Y. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.09.014 · Cited by 94
Self-citationZhang, W., Gao, Y., Li, F., Tong, X., Ren, Y., Han, X., Yao, S., Long, F., Yang, Z., Fan, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3396 · Cited by 96
Self-citationEph receptor function is modulated by heterooligomerization of A and B type Eph receptors
Janes, P. W., Griesshaber, B., Atapattu, L., Nievergall, E., Hii, L. L., Mensinga, A., Chheang, C., Day, B. W., Boyd, A., Bastiaens, P. I. H., et al. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201104037 · Cited by 93
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice
Stucci, L. S., Internò, V., Tucci, M., Perrone, M., Mannavola, F., Palmirotta, R., & Porta, C. (2021) · Genes · doi:10.3390/genes12050727 · Cited by 99
Romei, C., Casella, F., Tacito, A., Bottici, V., Valerio, L., Viola, D., Cappagli, V., Matrone, A., Ciampi, R., Piaggi, P., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103833 · Cited by 92
Human cancer databases (Review)
Pavlopoulou, A., Spandidos, D. A., & Michalopoulos, I. (2014) · Oncology Reports · doi:10.3892/or.2014.3579 · Cited by 97
Fallet, V., Saffroy, R., Girard, N., Mazières, J., Lantuéjoul, S., Vieira, T., Rouquette, I., Thivolet-Béjui, F., Ung, M., Poulot, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv232 · Cited by 91
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells
R�os, S., Flöter, J., Kaymak, I., Costa, C. D., Houddane, A., Dubuis, S., Griffiths, B. L., Mitter, R., Walz, S., Blake, S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.477 · Cited by 96
Porębska, N., Latko, M., Kucińska, M. K., Zakrzewska, M., Otlewski, J., & Opaliński, Ł. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010007 · Cited by 90
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment
Peña, C. G., Nakada, Y., Saatcioglu, H. D., Aloisio, G. M., Cuevas, I., Zhang, S., Miller, D. S., Lea, J. S., Wong, K., DeBerardinis, R. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82152 · Cited by 92
Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87
Mellor, P., Furber, L. A., Nyarko, J. N. K., & Anderson, D. H. (2011) · Biochemical Journal · doi:10.1042/bj20111164 · Cited by 95
Hao, C., Wang, L., Peng, S., Cao, M., Li, H., Hu, J., Huang, X., Liu, W., Zhang, H., Wu, S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.024 · Cited by 90
Self-citationDiscovery of co-occurring driver pathways in cancer
Zhang, J., Wu, L., Zhang, X., & Zhang, S. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-271 · Cited by 90
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development
Naser, R., Aldehaiman, A., Díaz‐Galicia, E., & Arold, S. T. (2018) · Cancers · doi:10.3390/cancers10060196 · Cited by 90
PathScan: a tool for discerning mutational significance in groups of putative cancer genes
Wendl, M. C., Wallis, J. W., Lin, L., Kandoth, C., Mardis, E. R., Wilson, R. K., & Li, J. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr193 · Cited by 91
Self-citationNiwa, O., Barcellos‐Hoff, M. H., Globus, R. K., Harrison, J. D., Hendry, J. H., Jacob, P., Martin, M. T., Seed, T. M., Shay, J. W., Story, M. D., et al. (2015) · Annals of the ICRP · doi:10.1177/0146645315595585 · Cited by 91
Translating genomic information into clinical medicine: Lung cancer as a paradigmPreprint
Levy, M. A., Lovly, C. M., & Pao, W. J. (2012) · Genome Research · doi:10.1101/gr.131128.111 · Cited by 89
Self-citationWu, L., Du, H., Li, Y., Qu, P., & Yan, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.028 · Cited by 89
Prognostic and predictive biomarkers in lung cancer. A review
Thunnissen, E., der Oord, K. V., & den Bakker, M. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1535-4 · Cited by 92
Carter, C. A., Rajan, A., Keen, C., Szabo, E. M., Khozin, S., Thomas, A., Brzezniak, C. E., Guha, U., Doyle, L. A., Steinberg, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw008 · Cited by 89
Frizzled7: A Promising Achilles’ Heel for Targeting the Wnt Receptor Complex to Treat Cancer
Phesse, T. J., Flanagan, D. J., & Vincan, E. (2016) · Cancers · doi:10.3390/cancers8050050 · Cited by 93
Integrated genetic and epigenetic analysis of myxofibrosarcoma
Ogura, K., Hosoda, F., Arai, Y., Nakamura, H. K., Hama, N., Totoki, Y., Yoshida, A., Nagai, M., Kato, M., Arakawa, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03891-9 · Cited by 94
Anusewicz, D., Orzechowska, M., & Bednarek, A. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-77284-8 · Cited by 89
Advances in Treatment of Lung Cancer With Targeted Therapy
Cagle, P. T., & Chirieac, L. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0618-ra · Cited by 89
Self-citationManagement and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
Gerber, D. E., Gandhi, L., & Costa, D. B. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e353 · Cited by 89
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Sauer, N. J., Szlasa, W., Jonderko, L., Oślizło, M., Kunachowicz, D., Kulbacka, J., & Karłowicz-Bodalska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179958 · Cited by 92
Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Gaykalova, D. A., Mambo, E., Choudhary, A. K., Houghton, J., Buddavarapu, K., Sanford, T., Darden, W., Adai, A. T., Hadd, A. G., Latham, G. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093102 · Cited by 92
Ovarian epithelial tumors and reproductive factors: a systematic review
Schüler, S., Ponnath, M., Engel, J. B., & Ortmann, O. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2784-1 · Cited by 92
Jung, S., Kim, M. S., Jung, C. K., Park, H.-C., Kim, S. Y., Liu, J., Bae, J. S., Lee, S. H., Kim, T., Lee, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11922 · Cited by 86
Tang, B., Xu, W., Wang, Y., Zhu, J., Wang, H., Tu, J., Weng, Q., Kong, C., Yang, Y., Qiu, R., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108872 · Cited by 87
Adetiba, E., & Olugbara, O. O. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/786013 · Cited by 87
Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M. D., Adusumilli, R., Breneiser, M., Byrne, M. N., Chung, L. P., Conneely, J., Crosby, L., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.06.004 · Cited by 89
MicroRNAs as lung cancer biomarkers
Vescovo, V. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.604 · Cited by 88
Chen, Y., Chen, G., Li, J., Huang, Y., Li, Y., Lin, J., Chen, L., Lu, J., Wang, Y., Wang, C., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11895 · Cited by 83
Chekhun, V. F., Sd, S., & Zd, S. (1985) · PubMed · Cited by 84
Kohno, T., Otsuka, A., Girard, L., Sato, M., Iwakawa, R., Ogiwara, H., Sánchez‐Céspedes, M., Minna, J. D., & Yokota, J. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20746 · Cited by 84
Hegde, G. V., de la Cruz, C. C., Chiu, C., Alag, N., Schaefer, G., Crocker, L., Ross, S., Goldenberg, D., Merchant, M. A., Tien, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004438 · Cited by 89
Clonal Architectures and Driver Mutations in Metastatic Melanomas
Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 85
Self-citationThe Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Smart, S. K., Vasileiadi, E., Wang, X., DeRyckere, D., & Graham, D. K. (2018) · Cancers · doi:10.3390/cancers10120474 · Cited by 87
Niida, H., Shimada, M., Murakami, H., & Nakanishi, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01719.x · Cited by 84
Andrechek, E. R., Cardiff, R. D., Chang, J. T., Gatza, M. L., Acharya, C. R., Potti, A., & Nevins, J. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901250106 · Cited by 82
Zhao, N., Wilkerson, M. D., Shah, U., Yin, X., Wang, A., Hayward, M. C., Roberts, P. J., Lee, C. B., Parsons, A. M., Thorne, L. B., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.013 · Cited by 84
Comprehensive molecular profiling of lung adenocarcinoma
Lander, E. S. (2014) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 84
Self-citationRoss, J. S., Gay, L. M., Wang, K., Ali, S. M., Chumsri, S., Elvin, J. A., Bose, R., Vergilio, J., Suh, J. H., Yelensky, R., et al. (2016) · Cancer · doi:10.1002/cncr.30102 · Cited by 84
Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment
Vail, M. E., Murone, C., Tan, A., Hii, L., Abebe, D., Janes, P. W., Lee, F.-T., Baer, M., Palath, V., Bebbington, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0218 · Cited by 83
Baldwin, A. E., Grueneberg, D. A., Hellner, K., Sawyer, J., Grace, M. R., Li, W., Harlow, E., & Münger, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007462107 · Cited by 83
Amplification of chromosomal segment 4q12 in non-small cell lung cancer
Ramos, A. H., Dutt, A., Mermel, C. H., Perner, S., Cho, J., Lafargue, C. J., Johnson, L. A., Stiedl, A., Tanaka, K., Bass, A. J., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9764 · Cited by 83
Self-citation
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
